Atazanavir: Its role in HIV treatment

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 6, 2008, Pages 785-796

  Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Atazanavir; Hyperbilirubinemia; Lipid profile; Protease inhibitor; Ritonavir

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTACID AGENT; ANTIVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; ATAZANAVIR PLUS SAQUINAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HISTAMINE H2 RECEPTOR ANTAGONIST; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RALTEGRAVIR; RIFAMPICIN; RIFAMYCIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OLIGOPEPTIDE; PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; KIDNEY FAILURE; LIPID BLOOD LEVEL; LIPODYSTROPHY; LIVER FUNCTION TEST; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MONOTHERAPY; MORBIDITY; MORTALITY; NEPHROLITHIASIS; NONHUMAN; PHARMACODYNAMICS; QRS COMPLEX; SIDE EFFECT; STONE FORMATION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS RESISTANCE; X RAY CRYSTALLOGRAPHY; CHEMISTRY; DRUG INTERACTION; FEMALE; PREGNANCY; REVIEW;

ANTI-HIV AGENTS; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; OLIGOPEPTIDES; PREGNANCY; PYRIDINES;

EID: 59449109075     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.6.785     Document Type: Article

References (94)

1. Schwarcz SK, Hsu LC, Vittinghoff E, Katz MH. Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996. Am. J. Epidemiol. 152(2), 178-185 (2000).
2. Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337(11), 734-739 (1997).
3. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352(9142), 1725-1730 (1998).
4. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338(13), 853-860 (1998).
5. Vittinghoff E, Scheer S, O'Malley P, et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J. Infect. Dis. 179(3), 717-720 (1999).
6. WHO. Towards Universal Access: Scaling-up Priority HIV/AIDS Interventions in the Health Sector. WHO HIV Department, Geneva, Switzerland (2007).
7. Gilks CF, Crowley S, Ekpini R et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368(9534), 505-510 (2006).
8. WHO. Report on WHO/UNAIDS Meeting on Forecasting ARV Needs Up to 2010: (Draft). WHO HIV Department, Geneva, Switzerland (2006).
9. WHO. Report on Prioritizing Second-Line Antiretroviral Drugs for Adults and Adolescent: a Public Health Approach. WHO HIV Department, Geneva, Switzerland (2007).
10. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. WHO HIV Department, Geneva, Switzerland (2006).
11. Desbois D, Roquebert B, Peytavin G et al. In vitro phenotypic susceptibility of HIV-2 clinical isolates to protease inhibitors. Antimicrob. Agents Chemother. 52(4), 1545-1548 (2008).
12. Brower ET, Bacha UM, Kawasaki Y, Freire E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem. Biol. Drug Des. 71(4), 298-305 (2008).
13. Brower ET, Bacha UM, Kawasaki Y, Freire E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem. Biol. Drug Des. 71(4), 298-305 (2008).
14. Gong Y-F, Robinson S, Rose RE et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. 44, 2319-2326 (2000).
15. Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving-containing regimens. J. Infect. Dis. 189, 1802-1810 (2004).
16. Herbert E. Klei, Kevin Kish et al. X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir. J. Virol. 81(17), 9525-9535.
17. Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 24(12), 1742-1747 (2004).
18. Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, von Moltke LL. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab. Dispos. 33(6), 764-770 (2005).
19. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 33(11), 1729-1739 (2005).
20. Colombo S, Buclin T, Cavassini M et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 50(11), 3801-3808 (2006).
21. Moltó J, Blanco A, Miranda C et al. Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice. Br. J. Clin. Pharmacol. 62(5), 560-566 (2006).
22. Higgins N, Zingman BS, Slish J et al. Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. Am. J. Addict. 16(6), 488-494 (2007).
23. Gonzalez de Requena D, Bonora S, Cavechia I et al. Atazanavir trough is associated with efficacy and safety at 24 weeks: definition of therapeutic range. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy. Québec, Canada, 28-30 April 2005 (Abstract 60).
24. Cleijsen RM, van de Ende ME, Kroon FP et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J. Antimicrob. Chemother. 60(4), 897-900 (2007).
25. Winston-A, Bloch M, Carr A et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J. Antimicrob. Chemother. 56(2), 380-387 (2005).
26. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S; AI424-007 Clinical Trial Group. Results of a Phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J. Acquir. Immune Defic. Syndr. 32(1), 18-29 (2003).
27. Murphy RL, Sanne I, Cahn P et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 17(18), 2603-2614 (2003).
28. Wood R, Phanuphak P, Cahn P et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J. Acquir. Immune Defic. Syndr. 36(2), 684-692 (2004).
29. Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. 36(5), 1011-1019 (2004).
30. Cohen C, Nieto-Cisneros L, Zala C et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr. Med. Res. Opin. 10, 1683-1692 (2005).
31. Johnson VA, Brun-Vézinet F, Clotet B et al. Drug resistance mutations in HIV-1. Top. HIV Med. 11(6), 215-221 (2003).
32. Malan N, Krantz E, David N et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects both with and without ritonavir: 96-week results from AI424-089. Presented at: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia, 22-25 July 2007 (Abstract WEPEB024).
33. Smith KY, Weinberg WG, Dejesus E et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/ emtricitabine, for the initial treatment of HIV Infection, 48-week results of ALERT. AIDS Res. Ther. 5(1), 5 (2008).
34. Molina J-M, Andrade-Villanueva J, Echevarria J et al. Efficacy and safety of once-daily atazanavir/ritonavir compared with twice daily lopinavir/ritonavir each in combination with tenofovir and emtricitabine ARV-naive HIV-1-infected subjects. The CASTLE study, 48-week results. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 25-28 February 2008.
35. Johnson M, Grinsztejn B, Rodriguez C et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 19(7), 685-694 (2005).
36. Johnson M, Grinsztejn B, Rodriguez C et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 20(5), 711-718 (2006).
37. Swindells S, DiRienzo AG, Wilkin T et al. Regimen simplification to atazanavir - ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 296(7), 806-814 (2006).
38. Vernazza P, Daneel S, Schiffer V et al. The role of compartment penetration in PI-monotherapy: the atazanavir - ritonavir monomaintenance (ATARITMO) trial. AIDS 21(10), 1309-1315 (2007).
39. Karlstrom O, Josephson F, Sonnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir monotherapy. J. Acquir. Immune Defic. Syndr. 44, 417-422 (2007).
40. Guffanti M, DePascalis CR, Seminari E et al. Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients. AIDS 217(18), 2669-2671 (2003).
41. Seminari E, Guffanti M, Villani P. Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsuals or amprenavir in HIV-infected patients. Eur. J. Clin. Pharmacol. 61(7), 545-549 (2005).
42. Winston A, Mallon PW, Satchell C et al. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation. Clin. Infect. Dis. 44(11), 1475-1483 (2007).
43. Khanlou H, Bhatti L, Fathing C. Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients. J. Acquir. Immune Defic. Syndr. 41(1), 124-125 (2006).
44. Malan D, Krantz E, Wirtz D et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J. Acquir. Immune Defic. Syndr. 47(2), 161-167 (2008).
45. Ribera E, Azuaje C, Lopez RM et al. Atazanavir and lopinavir/ ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS 12(8), 1131-1139 (2006).
46. Gilliam BL, Chan-Tack KM, Qaqish RB, Rode RA, Fantry LE, Redfield RR. Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and proteaseinhibitor-restant HIV-infected patients. AIDS Patient Care STDS 20(11), 745-759 (2006).
47. von Hentig N, Kaykhin P, Stephan C et al. Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen. Antimicrob. Agents Chemother. 52(6), 2273-2275 (2008).
48. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin. Pharmacokinet. 43(15), 1071-1087 (2004).
49. Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 17, 1195-1199 (2003).
50. Acosta EP, Bardeguez A, Zorrilla CD et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob. Agents Chemother. 48, 430-436 (2004).
51. Stek AM, Mirochnick M, Capparelli M et al. Reduced lopinavir exposure during pregnancy. AIDS 20, 1931-1939 (2006).
52. Natha M, Hay P, Taylor G et al. Atazanavir use in pregnancy: a report of 33 cases. Presented at: 14 Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25-28 February 2007 (Poster 750).
53. Ripamonti D, Cattaneo D, Maggiolo F et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 21(18), 2409-2415 (2007).
54. Chappuy H, Tréluyer JM, Jullien V et al. Maternal - fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob. Agents Chemother. 48, 4332-4336 (2004).
55. Marzolini C, Rudin C, Decosterd LA et al. Transplacental passage of protease inhibitors at delivery. AIDS 16(6), 889-893 (2002).
56. Gingelmaier A, Kurowski M, Kästner R et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 20(13), 1737-1743 (2006).
57. Mirochnick M, Dorenbaum A, Holland D et al. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr. Infect. Dis. J. 21(9), 835-838 (2002).
58. Chappuy H, Tréluyer JM, Rey E et al. Maternal - fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am. J. Obstet. Gynecol. 191(2), 558-562 (2004).
59. Lechelt M, Lyons F, Clarke A, Magaya V, Issa R, de Ruiter A. Human placental transfer of atazanavir: a case report. AIDS 20(2), 307 (2006).
60. Dumond JB, Yeh RF, Patterson KB et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 21(14), 1899-1907 (2007).
61. Pilcher CD, Joaki G, Hoffman IF et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 21, 1723-1730 (2007).
62. van Leeuwen E, Ter Heine R, van der Veen F, Repping S, Beijnen JH, Prins JM. Penetration of acazanavir in seminal plasma of men infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 51(1), 335-337 (2007).
63. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Suscepibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and post exposure prophylaxis. Antivir. Ther. 9(1), 57-65 (2004).
64. Masse S, Lu X, Dekhtyar T et al. In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Antimicrob. Agents Chemother. 51(9), 3075-3080 (2007).
65. Taburet AM, Piketty C, Chazallon C et al. Interactions between atazanavir - ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48(6), 2091-2096 (2004).
66. Dailly E, Tribut O, Tattevan P et al. Influence of tenofovir, nevirapine and evavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected individuals. Eur. J. Clin. Pharmacol. 62(7), 523-526 (2006).
67. Von Hentig N, Dauer B, Haberi A et al. Tenofovir comedication does not impair steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected adults. Eur. J. Clin. Pharmacol. 63(10), 935-940 (2007).
68. Beique L, Giguere P, la Porte C, Angel J. Interactions between protease inhibitors and acid-reducing agents: a systematic review. HIV Med. 8, 335-345 (2007).
69. Fulco PP, Vora UB, Bearman GM. Acid suppressive therapy and the effects on protease inhibitors. Ann. Pharmacother. 40(11), 1974-1983 (2006).
70. van Lunzen J, Liess H, Arastéh K, Walli R, Daut B, Schürmann D. Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy. HIV Med. 8(4), 220-225 (2007).
71. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systemic review. Pharmacotherapy 23, 460-471 (2003).
72. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practicing physician needs to know. Drugs 63, 2739-2754 (2003).
73. Tomilo DL, Smith PF, Ogundele AB et al. Inhibition of atazanavir oral absorption in lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy 26, 341-346 (2006).
74. Antoniou T, Yoong D, Beique L et al. Impact of acid-suppressive therapy on virologic response to atazanavir-based regimens in antiretroviral-experienced patients: a case series J. Acquir. Immune Defic. Syndr. 39(1), 126-128 (2005).
75. Acosta EP, Kendall MA, Gerber JG et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob. Agents Chemother. 51(9), 3104-3110 (2007).
76. Pineda JA, Santos J, Rivero A et al. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients coinfected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. J. Antimicrob. Chemother. 61(4), 925-932 (2008).
77. Slish J, Ma Q, Zingman BS et al. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. Ther. Drug Monit. 29(5), 560-565 (2007).
78. Colafigli M, Di Giambenedetto S, Bracciale L, Tamburrini E, Cauda R, De Luca A. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. HIV Med. 9(3), 172-179 (2008).
79. Hruz PW, Yan Q, Struthers H, Jay PY. HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy. FASEB J. 22(7), 2161-2167 (2008).
80. Busti AJ, Tsikouris JP, Peeters MJ et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med. 7(5), 317-322 (2006).
81. Gianotti N, Guffanti M, Galli L et al. Electrocardiographic changes in HIV-infected drug-experienced patients being treated with atazanavir. AIDS 21(12), 1648-1651) (2007).
82. Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am. J. Kidney Dis. 44(5), E81-E84 (2004).
83. Möddel M, Pfammatter R, Varga Z, Keusch G. Acute tubulointerstitial nephritis in HIV infection. Praxis (Bern 1994) 95(23), 949-951 (2006).
84. Schmid S, Opravil M, Moddel M et al. Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Arch. 450(6), 665-670 (2007).
85. Change HR, Pella PM. Atazanavir urolithiasis. N. Engl. J. Med. 355, 2158-2159 (2006).
86. Pacanowski J, Poirier J-M, Petit I, Meynard J-L, Girard P-M. Atazanavir urinary stones in an HIV-infected patient. AIDS 20, 2130-2131 (2006).
87. Moriyama Y, Minamidate Y, Yasuda M et al. Acute renal failure due to bilateral ureteral stone impaction in an HIV-positive patient. Urol. Res. 36(5), 275-277 (2008).
88. Anderson PL, Lichtenstein KA, Gerig NE, Kiser JJ, Bushman LR. Atazanavir-containing renal calculi in an HIV-infected patient. AIDS 21, 1060-1061 (2007).
89. Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's adverse event reporting system. AIDS 21(9), 1215-1218 (2007).
90. Gatell J, Salmon-Ceron D, Lazzarin A et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48-week results. Clin. Infect. Dis. 44, 1484-1492 (2007).
91. Mallolas J, Podzamczer D, Domingo P et al. Efficacy and safety of switching from lopinavir/r (LPV/r) to atazanavir/r (/r) in patients with virological suppression receiving a LPV/r containing HAART: the ATAZIP study. Presented at: 4th IAS Conference on HIV pathogenesis and Treatment. Sydney, Australia, 22-25 July 2007 (Abstract WEPEB117LB.)
92. Jemsek JG, Arathoon E, Arlotti M et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin. Infect. Dis. 42, 273-280 (2006).
93. McGrath D, Frederick D, Wirtz V et al. Body composition changes in ART-naive subjects treated with atazanavir or atazanavir/ritonavir-based once daily HAART: 48-week computed tomography and DEXA data. Presented at: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA, 25-28 February 2007 (Poster 804).
94. Steinbrook R. Closing the affordability gap for drugs in low-income countries. N. Engl. J. Med. 35(20), 1996-1999 (2007).